CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy
Stratification of the prognosis of pancreatic cancer (PDAC) patients treated by surgery is based solely on clinical variables, such as tumor stage and node status. The development of biomarkers of relapse is needed, especially to drive administration of adjuvant therapy in this at-risk population. O...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2294563 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846142227356581888 |
|---|---|
| author | Coralie Schoumacher Valentin Derangère Gwladys Gaudillière-Le Dain Titouan Huppe David Rageot Alis Ilie Angélique Vienot Christophe Borg Franck Monnien Frederic Bibeau Caroline Truntzer François Ghiringhelli |
| author_facet | Coralie Schoumacher Valentin Derangère Gwladys Gaudillière-Le Dain Titouan Huppe David Rageot Alis Ilie Angélique Vienot Christophe Borg Franck Monnien Frederic Bibeau Caroline Truntzer François Ghiringhelli |
| author_sort | Coralie Schoumacher |
| collection | DOAJ |
| description | Stratification of the prognosis of pancreatic cancer (PDAC) patients treated by surgery is based solely on clinical variables, such as tumor stage and node status. The development of biomarkers of relapse is needed, especially to drive administration of adjuvant therapy in this at-risk population. Our study evaluates the prognostic performance of a CD3- and CD8-based immune score. CD3, CD8 and Foxp3 expression were evaluated on whole slides in two retrospective PDAC cohorts totaling 334 patients. For this study, we developed an immune score to estimate CD3 and CD8 infiltration in both tumor core and invasive margin using computer-guided analysis with QuPath software. Variables were combined in a dichotomous immune score. The association between immune and clinical scores, and both PFS and OS was investigated. We observed that a dichotomous immune score predicts both PFS and OS of localized PDAC. By univariate and multivariate analysis, immune score, tumor grade, adjuvant therapy, lymph node status, and adjuvant chemotherapy administration were associated with PFS and OS. We subsequently associated the PDAC immune score and clinical variables in a combined score. This combined score predicted patient outcomes independently of adjuvant or neoadjuvant treatment, and improved patient prognostic prediction compared to clinical variables or immune score alone. |
| format | Article |
| id | doaj-art-d7de998b11554bb3986b1833080f8892 |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-d7de998b11554bb3986b1833080f88922024-12-03T13:49:34ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2023.2294563CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapyCoralie Schoumacher0Valentin Derangère1Gwladys Gaudillière-Le Dain2Titouan Huppe3David Rageot4Alis Ilie5Angélique Vienot6Christophe Borg7Franck Monnien8Frederic Bibeau9Caroline Truntzer10François Ghiringhelli11Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, FranceCancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, FranceCancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, FranceCancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, FranceCancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, FranceCancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, FranceDepartment of Medical Oncology, CHU Besançon, Besançon, FranceDepartment of Medical Oncology, CHU Besançon, Besançon, FranceDepartment of Pathology, CHU Besançon, Besançon, FranceDepartment of Pathology, CHU Besançon, Besançon, FranceCancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, FranceCancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, FranceStratification of the prognosis of pancreatic cancer (PDAC) patients treated by surgery is based solely on clinical variables, such as tumor stage and node status. The development of biomarkers of relapse is needed, especially to drive administration of adjuvant therapy in this at-risk population. Our study evaluates the prognostic performance of a CD3- and CD8-based immune score. CD3, CD8 and Foxp3 expression were evaluated on whole slides in two retrospective PDAC cohorts totaling 334 patients. For this study, we developed an immune score to estimate CD3 and CD8 infiltration in both tumor core and invasive margin using computer-guided analysis with QuPath software. Variables were combined in a dichotomous immune score. The association between immune and clinical scores, and both PFS and OS was investigated. We observed that a dichotomous immune score predicts both PFS and OS of localized PDAC. By univariate and multivariate analysis, immune score, tumor grade, adjuvant therapy, lymph node status, and adjuvant chemotherapy administration were associated with PFS and OS. We subsequently associated the PDAC immune score and clinical variables in a combined score. This combined score predicted patient outcomes independently of adjuvant or neoadjuvant treatment, and improved patient prognostic prediction compared to clinical variables or immune score alone.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2294563BiomarkersCD3CD8immune scorePDACprognostic |
| spellingShingle | Coralie Schoumacher Valentin Derangère Gwladys Gaudillière-Le Dain Titouan Huppe David Rageot Alis Ilie Angélique Vienot Christophe Borg Franck Monnien Frederic Bibeau Caroline Truntzer François Ghiringhelli CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy OncoImmunology Biomarkers CD3 CD8 immune score PDAC prognostic |
| title | CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy |
| title_full | CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy |
| title_fullStr | CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy |
| title_full_unstemmed | CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy |
| title_short | CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy |
| title_sort | cd3 cd8 immune score associated with a clinical score stratifies pdac prognosis regardless of adjuvant or neoadjuvant chemotherapy |
| topic | Biomarkers CD3 CD8 immune score PDAC prognostic |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2294563 |
| work_keys_str_mv | AT coralieschoumacher cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT valentinderangere cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT gwladysgaudilliereledain cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT titouanhuppe cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT davidrageot cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT alisilie cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT angeliquevienot cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT christopheborg cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT franckmonnien cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT fredericbibeau cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT carolinetruntzer cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy AT francoisghiringhelli cd3cd8immunescoreassociatedwithaclinicalscorestratifiespdacprognosisregardlessofadjuvantorneoadjuvantchemotherapy |